Show Me More

Blood Pressure Management: Treating to Target

The Canadian Hypertension Education Program (CHEP) provides clinicians with guidance on the ramifications, monitoring, and treatment of hypertension. These guidelines are available at http://hypertension.ca. This module offers a focused review of the CHEP treatment guidelines that will enable you to contribute to improved CV outcomes for your patients.

Author: Michael Boivin, B. Sc. Phm.

Reviewer: Tom Smiley RPh, BScPhm, PharmD

Combination Estrogen-Progestin Patch and Vaginal Ring

For patients seeking hormonal contraception without a daily pill, this lesson details the proper use of the transdermal patch and vaginal ring. Also addresses efficacy, safety and adverse effects.

After completion of this program pharmacists will be better able to:

Educate patients on the efficacy of the transdermal contraceptive patch and vaginal contraceptive ring, and compare them to the combination oral contraceptive (COC).
Educate patients on the long-term safety and adverse effects of the transdermal contraceptive patch and vaginal contraceptive ring, and in comparison to COCs.
Answer patients' questions regarding missed doses and prolonged administration of the transdermal contraceptive patch and vaginal contraceptive ring.
Educate patients on proper dosing and administration of the transdermal contraceptive patch and vaginal contraceptive ring.

Author: Tom Smiley RPh, BScPhm, PharmD

Reviewers: Nora MacLeod-Glover RPh, BScPhm, PharmD, Michael Boivin RPh, BScPhm

Accredited for 0.5 CE units, CCCEP File # 1057-2010-165-I-P (Expires Dec. 3, 2013)

Combination Oral Contraception: Safety and Adverse Effects

Author: Michael Boivin, B. Sc. Phm.

Reviewer: Tom Smiley RPh, BScPhm, PharmD

Estrogen-Progestin Combination Oral Contraception

Help patients separate facts from fiction regarding long-term use of COCs. This lesson also addresses breakthrough bleeding and potential drug interactions.

Upon completion of this program, pharmacists will be better able to:

Discuss long-term risks of combination oral contraception (COC).
Individualize COC recommendations based on estrogen and progestational activity of product.
Advise women on how to prevent and/or manage breakthrough bleeding associated with COC use.
Assess the appropriateness of COC for a woman based on absolute and relative contraindications and potential for drug interactions with current medications.

Author: Tom Smiley RPh, BScPhm, PharmD

Reviewers: Nora MacLeod-Glover RPh, BScPhm, PharmD, Michael Boivin RPh, BScPhm

Accredited for 0.5 CE units, CCCEP File # 1057-2010-165-I-P (Expires Dec. 3, 2013)

Glycemic Targets and Macrovascular Complications

Educate patients on the role and targets of blood glucose monitoring and A1C, and how to manage risk factors associated with hypertension and dyslipidemia.

After completion of this program, pharmacists will be better able to:

Suggest diabetes screening recommendations to their patients, based on the Canadian Diabetes Association 2008 Clinical Practice Guidelines.
Educate patients on the role and targets of:
- Self-monitoring of blood glucose (SMBG).
- A1C.
Counsel patients on the role of diabetes in the development of macrovascular complications and of controlling the modifiable risk factors of:
- Hypertension.
- Dyslipidemia.

Author: Michael Boivin RPh, BScPhm

Reviewers: Nora MacLeod-Glover RPh, BScPhm, PharmD, Tom Smiley RPh, BScPhm, PharmD

Accredited for 0.5 CE units, CCCEP File # 1057-2010-168-I-P (Expires Dec. 11, 2013)

Intrauterine Devices and Barrier Contraceptives

After completion of this continuing education module pharmacists will be better able to:

Discuss the benefits and risks of the levonorgestrel intrauterine device.
Discuss the benefits and risks of the copper intrauterine device.
Outline the benefits and risks of barrier contraceptive methods that include the male condom, female condom, diaphragm and contraceptive sponge.
Recommend non-hormonal options for women who prefer not to use products containing estrogen or progestin for contraceptive purposes.

Author: Tom Smiley RPh, BScPhm, PharmD

Reviewers: Nora MacLeod-Glover RPh, BScPhm, PharmD, Michael Boivin RPh, BScPhm

Accredited for 0.5 CE units, CCCEP File # 1057-2010-165-I-P (Expires Dec. 3, 2013)

Lifestyle Modification for Management of Diabetes and Prediabetes

After completion of this continuing education module, nurses will be better able to:

Discuss the epidemiology of diabetes in Canada.
Educate patients on the diagnostic differences between prediabetes and type 2 diabetes.
Counsel patients about diabetes risk factors and the prevention of diabetes.
Recommend positive lifestyle modifications to help patients manage diabetes and prediabetes.

Author: Michael Boivin, B. Sc. Phm.

Reviewer: Tom Smiley RPh, BScPhm, PharmD

Lifestyle Treatment Options for Diabetes and Prediabetes

A concise review of the pharmacist's role in educating patients about diabetes risk factors and the prevention of diabetes, as well as how to support their diet and fitness goals.

After completion of this program pharmacists will be better able to:

Discuss the epidemiology of diabetes in Canada.
Educate patients on the diagnostic differences between prediabetes and type 2 diabetes.
Counsel patients about diabetes risk factors and the prevention of diabetes.
Recommend positive lifestyle modifications to help patients manage diabetes and prediabetes.

Author: Tom Smiley RPh, BScPhm, PharmD

Reviewers: Nora MacLeod-Glover RPh, BScPhm, PharmD, Michael Boivin RPh, BScPhm

Accredited for 0.5 CE units, CCCEP File # 1057-2010-168-I-P (Expires Dec. 3, 2013)

Oral Hypoglycemic Medications and Insulin Initiation

Educate patients on the treatment options for type 2 diabetes and the importance of adherence, as well as how to identify and treat hypoglycemia.

After completion of this program, pharmacists will be better able to:

Counsel patients on the importance of medication adherence in type 2 diabetes.
Discuss the different treatment options for type 2 diabetes.
Educate a patient on the initiation of basal insulin in type 2 diabetes.
Educate a patient on the identification and treatment of hypoglycemia.

Author: Michael Boivin RPh, BScPhm

Reviewers: Nora MacLeod-Glover RPh, BScPhm, PharmD, Tom Smiley RPh, BScPhm, PharmD

Accredited for 0.5 CE units, CCCEP File # 1057-2010-168-I-P (Expires Dec. 11, 2013)

Taking Careful Steps to Manage Fragility Fractures: A 2011 Update, Background and Risk Assessment

Based on the 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada, which focuses on the prevention of fragility fractures, this education module presents an updated review of the impact of fragility fractures and examines the use of risk factor assessment tools to assess patients' 10-year risk of a major osteoporotic fracture.

After completion of this continuing education program, participants will be better able to:

Discuss the impact of fragility fractures secondary to osteoporosis on health and quality of life.
Define osteoporosis and the pathophysiology that increases risk for fragility fracture.
Assess risk for fragility fracture according to current Canadian guideline standards.
Identify and modify patient circumstances that increase risk for fragility fractures.
Refer patients for bone mineral density testing based on current Canadian guideline assessment standards.

Author: Tom Smiley RPh, BScPhm, PharmD

Taking Careful Steps to Manage Fragility Fractures: A 2011 Update, Guidelines for Prevention and Management

Healthcare providers, particularly in long-term care settings, play a critical role in the prevention and management of fragility fractures secondary to osteoporosis. Based on the 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada, this program outlines prevention strategies, lifestyle modification measures, ongoing patient assessment and pharmacotherapy according to patient circumstances.

After completion of this continuing education program participants will be better able to:

Discuss fall prevention strategies.
Educate patients about lifestyle measures which reduce risk for osteoporosis.
Recommend appropriate intake of calcium and vitamin D from all sources.
Discuss benefits and risks associated with the pharmacological treatment of osteoporosis.
Discuss current evidence regarding risks associated with bisphosphonate treatment and supplemental calcium, which have recently received media attention.

Author: Tom Smiley RPh, BScPhm, PharmD

Subscribe to our Newsletter

Register

Being a member of the Health eLearning portal gives you extra privileges, such as free CE, access to insights from leading experts, industry news, and more. Click here to register.

Recommend to a Friend

Spread the word! Let your colleagues know about HealtheLearning.ca - for each person who registers, you'll be entered an additional time in the contest.

Recommend this site to a friend.

Search Site

Find Us Online

| | |

Why Should I Join?

At Health eLearning, you'll find continuing education, certification-level training and patient education materials that embrace and enable your growing role in the delivery of health care. This comprehensive site provides tools to share with patients, including handouts and medical screening devices. Being a member of the Health eLearning portal gives you extra privileges, such as free CE, access to insights from leading experts, industry news, and more. At Health eLearning, our interactive approach will make us your first choice for professional education.